PMS50 Benefits in Patient Reported Outcomes Supporting a “Treat to Target” Paradigm for Infliximab -Treated RA Patients Previously Inadequately Responsive to Prior Anti-TNF Treatment
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.239
https://www.valueinhealthjournal.com/article/S1098-3015(12)00304-X/fulltext
Title :
PMS50 Benefits in Patient Reported Outcomes Supporting a “Treat to Target” Paradigm for Infliximab -Treated RA Patients Previously Inadequately Responsive to Prior Anti-TNF Treatment
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00304-X&doi=10.1016/j.jval.2012.03.239
First page :
A42
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
1013